ABSTRACT
<p><b>OBJECTIVE</b>To assist decision-makers interpret and choose among conflfl icting meta-analyses, as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (, SC) plus chemotherapy versus chemotherapy of non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC. Meta-analyses only composed of randomized controlled trials (RCTs) met the inclusion criteria. Two authors individually estimated the quality of meta-analysis and extracted data. The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence.</p><p><b>RESULTS</b>A total of 5 meta-analyses were included. All the studies composed of RCTs or quasi-RCTs and were regarded as level-II evidence. The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6 (median 4). A high-quality meta-analysis with more RCTs was chosen, which suggested that SC plus chemotherapy could increase incidence of short-term efficacy, improve the quality of life and survival rate in comparison to chemotherapy. However, there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect, such as liver and kidney function obstacle, leukopenia, hemoglobin decrement and gastrointestinal adverse reaction.</p><p><b>CONCLUSIONS</b>Based on the best available evidence, treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects. Therefore, SC plus chemotherapy may be superior to chemotherapy for treating NSCLC. However, due to some limitations, SC plus chemotherapy should be cautiously considered, and further high-quality meta-analyses are needed.</p>
Subject(s)
Humans , Algorithms , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Carcinoma, Non-Small-Cell Lung , Drug Therapy , Drugs, Chinese Herbal , Therapeutic Uses , Lung Neoplasms , Drug TherapyABSTRACT
Objective To explore clinical effect and life quality study of Shenyi capsule combined with docetaxel and cisplatin in treatment of advanced breast cancer.Methods 135 cases of advanced breast cancer of Huangshi Central Hospital were collected and diagnosed from July 2013 to December 2014 in accordance with the random number table,were divided into treatment group(n=69) and control group(n=66).Both groups were given regular basis treatment, control group was treated by docetaxel(75 mg/m2,twice a day)and cisplatin(25 mg/m2,once a day), and treatment group combined with Shenyi capsule(20 mg,twice a day)on the basis of control group treatment.4 weeks were 1 course, and all the cases were taken 12 weeks of continuous treatment.Observed and compared the clinical efficiency and life quality of two groups.Results The remission rate of 63.77% in treatment group was higher than control group of 40.91%, difference was statistically significant(χ2 =7.070,P=0.008).After treatment, the SF-36 scale in treatment group significantly increased from ( 54.69 ±8.78 ) to ( 63.87 ±12.08 ) , and higher than that of control group ( 57.95 ±11.95 ) , differences were statistically significant(P<0.05).The adverse reactions in treatment group was lower than control group, difference was statistically significant(Z=2.858,P =0.000).Conclusion The clinical effect in treatment of advanced breast canceris obvious by Shenyi capsule combined docetaxel and cisplatin.It can significantly improve clinical effect and life quality.
ABSTRACT
AIM: To explore the roles of vascular endothelial growth factor (VEGF) in hypoxia pulmonary hypertension and effects of SHENYI Capsule. METHODS: Thirty SD rats were randomly divided into normal control group (N), hypoxia hypercapnia group (F), and hypoxia hypercapnia+SHENYI Capsule group (S). The levels of VEGF in serum and lung tissue are measured by ELISA, the ultrastructure of pulmonary arterioles was observed by electron microscopy, and the expression of VEGFmRNA was observed by in situ hybirdization. RESULTS: Mean pulmonary arterial pressure (mPAP), weight ratio of RV to LV+S, the levels of VEGF in serum, and lung tissue of group F were significantly higher than those of group N and group S (P